XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
Journal for ImmunoTherapy of Cancer · 2023-12 · 11 (12) · e007785
DOI: 10.1136/jitc-2023-007785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 12.12.2023. Verfasst von Kurt A Jenkins und 18 weiteren Autor:innen. Beteiligte Einrichtung: Xilio Therapeutics, Waltham, Massachusetts, USA kjenkins@xiliotx.com. Hauptthemen laut MEDLINE: Antineoplastic Agents, Melanoma. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Xilio Therapeutics, Inc, National Institutes of Health.
Abstract (Originalsprache)
Introduction
The clinical benefit of the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab has been well established but limited by immune-related adverse events, especially when ipilimumab is used in combination with anti-PD-(L)1 mAb therapy. To overcome these limitations, we have developed XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 mAb.
Methods
XTX101 consists of an anti-human CTLA-4 mAb covalently linked to masking peptides that block the complementarity-determining regions, thereby minimizing the mAb binding to CTLA-4. The masking peptides are designed to be released by proteases that are typically dysregulated within the tumor microenvironment (TME), resulting in activation of XTX101 intratumorally. Mutations within the Fc region of XTX101 were included to enhance affinity for FcγRIII, which is expected to enhance potency through antibody-dependent cellular cytotoxicity.
Results
Biophysical, biochemical, and cell-based assays demonstrate that the function of XTX101 depends on proteolytic activation. In human CTLA-4 transgenic mice, XTX101 monotherapy demonstrated significant tumor growth inhibition (TGI) including complete responses, increased intratumoral CD8+T cells, and regulatory T cell depletion within the TME while maintaining minimal pharmacodynamic effects in the periphery. XTX101 in combination with anti-PD-1 mAb treatment resulted in significant TGI and was well tolerated in mice. XTX101 was activated in primary human tumors across a range of tumor types including melanoma, renal cell carcinoma, colon cancer and lung cancer in an ex vivo assay system.
Conclusions
These data demonstrate that XTX101 retains the full potency of an Fc-enhanced CTLA-4 antagonist within the TME while minimizing the activity in non-tumor tissue, supporting the further evaluation of XTX101 in clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xilio Therapeutics, Waltham, Massachusetts, USA kjenkins@xiliotx.com.
- Molecular Medicine, City of Hope National Medical Center, Beckman Research Institute, Duarte, California, USA.
- Xilio Therapeutics, Waltham, Massachusetts, USA.
- Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Kurt A Jenkins, John C Williams
Förderung
- NCI NIH HHS
- Xilio Therapeutics, Inc
- National Institutes of Health
Zitieren
APA
Jenkins, K. A., Park, M., Pederzoli-Ribeil, M., Eskiocak, U., Johnson, P., Guzman, W., McLaughlin, M., Moore-Lai, D., O'Toole, C., Liu, Z., Nicholson, B., Flesch, V., Qiu, H., Clackson, T., O'Hagan, R. C., Rodeck, U., Karow, M., O'Neil, J., & Williams, J. C. (2023). XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer. Journal for ImmunoTherapy of Cancer, 11(12), e007785. https://doi.org/10.1136/jitc-2023-007785
Vancouver
Jenkins KA, Park M, Pederzoli-Ribeil M, Eskiocak U, Johnson P, Guzman W, et al. XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer. Journal for ImmunoTherapy of Cancer. 2023;11(12):e007785. doi:10.1136/jitc-2023-007785
BibTeX
@article{Jenkins2023,
author = {Jenkins, Kurt A and Park, Miso and Pederzoli-Ribeil, Magali and Eskiocak, Ugur and Johnson, Parker and Guzman, Wilson and McLaughlin, Megan and Moore-Lai, Deborah and O'Toole, Caitlin and Liu, Zhen and Nicholson, Benjamin and Flesch, Veronica and Qiu, Huawei and Clackson, Tim and O'Hagan, Ronan C and Rodeck, Ulrich and Karow, Margaret and O'Neil, Jennifer and Williams, John C},
title = {XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {12},
pages = {e007785},
doi = {10.1136/jitc-2023-007785}
}
EUVIMED